Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;23(2):106-12.
doi: 10.1016/j.smim.2011.01.016.

Toll-like receptor driven B cell activation in the induction of systemic autoimmunity

Affiliations
Review

Toll-like receptor driven B cell activation in the induction of systemic autoimmunity

Nathaniel M Green et al. Semin Immunol. 2011 Apr.

Abstract

Studies over the past decade have demonstrated a key role for pattern recognition receptors in the activation of autoreactive B cells. Self reactive B cells that manage to escape negative selection often express relatively low affinity receptors for self antigens (ignorant B cells), and can only be activated by integrating a relatively weak BCR signal with signals from additional receptors. Members of the toll-like receptor (TLR) gene family, and especially the nucleic acid binding receptors TLR 7, 8 and 9, appear to play a key role in this regard and promote the production of autoantibodies reactive with DNA- or RNA-associated autoantigens. These autoantibodies are able to form immune complexes with soluble or cell-bound ligands, and these immune complexes can in turn activate a second round of proinflammatory cells that further contribute to the autoimmune disease process. Recent data have emerged showing a pathogenic role for TLR7, with an opposing, protective role for TLR9. Targeting these disregulated pathways offers a therapeutic opportunity to treat autoimmune diseases without crippling the entire immune system. Further understanding of the role of specific receptors, cell subsets, and inhibitory signals that govern these TLR-associated pathways will enable future therapeutics to be tailored to specific categories of autoimmune disease.

PubMed Disclaimer

References

    1. von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995;24:323–358. - PubMed
    1. Nakamura RM, Tan EM. Autoantibodies to nonhistone nuclear antigens and their clinical significance. Hum Pathol. 1983;14:392–400. - PubMed
    1. Chung L, Utz PJ. Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheumatol Rep. 2004;6:156–163. - PubMed
    1. Alspaugh MA, Talal N, Tan EM. Differentiation and characterization of autoantibodies and their antigens in Sjogren's syndrome. Arthritis Rheum. 1976;19:216–222. - PubMed
    1. Schmid G, Fricke L, Lange HW, Heidland A. Intracellular histidine content of various tissues (brain, striated muscle and liver) in experimental chronic renal failure. Klin Wochenschr. 1977;55:583–585. - PubMed